Futura has developed a highly efficient and proprietary delivery technology, DermaSys®, for the absorption of active molecules through the skin. The DermaSys® technology was originally developed by Futura for use in our topical treatment for erectile dysfunction, MED2002. DermaSys® is a versatile and bespoke technology in that it can be tailored to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects.
Futura has signed an agreement with a global pharmaceutical and healthcare group GlaxoSmithKline plc for the development and potential commercialisation of TPR100, our topically applied product for pain relief, which incorporates the DermaSys® technology platform.
To further maximise the value of this asset, Futura has been evaluating its use with a range of compounds and in a range of indications.In the process of developing PET500, Futura also expanded its DermaSys® delivery technology platform and produced a new and unique delivery system which does not contain water, DermaSys® AquaFree.